Who
Paul A. Friedman
Director
Company insider
Files Form 4 as: Director, Prelude Therapeutics; Chief Executive Officer, Madrigal Pharmaceuticals; Director, Alexion Pharmaceuticals; Chief Executive Officer, Incyte; Director, Dare Bioscience; Director, Verastem; Director, Auxilium Pharmaceuticals; Director, Durata Therapeutics.
In numbers
- Trades disclosed
- 432
- Buys
- 13
- Sells
- 36
- Bought
- $1.4M
- Sold
- $337.3M
- Companies
- 10
- Companies where not an officer
- 8
- First trade
- 13 Jan 2006
- Last trade
- 9 Jun 2026
- Last filed
- 10 Jun 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 9 Jun 2026filed 10 Jun 2026 | PRLD Prelude Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —38,000 at $0.00 | filing |
| 9 Jun 2026filed 10 Jun 2026 | PRLD Prelude Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —38,000 at $0.00 | filing |
| 9 Jan 2026filed 13 Jan 2026 | MDGL Madrigal PharmaceuticalsPharmaceuticals | SEC FORM 4 Code M | $387K24,520 at $15.80 | filing |
| 9 Jan 2026filed 13 Jan 2026 | MDGL Madrigal PharmaceuticalsPharmaceuticals | SEC FORM 4 Sold | $355K681 at $521.03 | filing |
| 9 Jan 2026filed 13 Jan 2026 | MDGL Madrigal PharmaceuticalsPharmaceuticals | SEC FORM 4 Sold | $438K840 at $521.98 | filing |
| 9 Jan 2026filed 13 Jan 2026 | MDGL Madrigal PharmaceuticalsPharmaceuticals | SEC FORM 4 Sold | $507K970 at $523.00 | filing |
| 9 Jan 2026filed 13 Jan 2026 | MDGL Madrigal PharmaceuticalsPharmaceuticals | SEC FORM 4 Sold | $628K1,199 at $524.10 | filing |
| 9 Jan 2026filed 13 Jan 2026 | MDGL Madrigal PharmaceuticalsPharmaceuticals | SEC FORM 4 Sold | $1.3M2,432 at $525.05 | filing |
| 9 Jan 2026filed 13 Jan 2026 | MDGL Madrigal PharmaceuticalsPharmaceuticals | SEC FORM 4 Sold | $561K1,066 at $526.00 | filing |
| 9 Jan 2026filed 13 Jan 2026 | MDGL Madrigal PharmaceuticalsPharmaceuticals | SEC FORM 4 Sold | $822K1,560 at $526.97 | filing |
| 9 Jan 2026filed 13 Jan 2026 | MDGL Madrigal PharmaceuticalsPharmaceuticals | SEC FORM 4 Sold | $304K575 at $528.18 | filing |
| 9 Jan 2026filed 13 Jan 2026 | MDGL Madrigal PharmaceuticalsPharmaceuticals | SEC FORM 4 Sold | $366K691 at $529.17 | filing |
| 9 Jan 2026filed 13 Jan 2026 | MDGL Madrigal PharmaceuticalsPharmaceuticals | SEC FORM 4 Sold | $88K166 at $529.76 | filing |
| 9 Jan 2026filed 13 Jan 2026 | MDGL Madrigal PharmaceuticalsPharmaceuticals | SEC FORM 4 Sold | $758K1,480 at $511.98 | filing |
| 9 Jan 2026filed 13 Jan 2026 | MDGL Madrigal PharmaceuticalsPharmaceuticals | SEC FORM 4 Sold | $149K280 at $530.69 | filing |
| 9 Jan 2026filed 13 Jan 2026 | MDGL Madrigal PharmaceuticalsPharmaceuticals | SEC FORM 4 Sold | $43K80 at $532.50 | filing |
| 9 Jan 2026filed 13 Jan 2026 | MDGL Madrigal PharmaceuticalsPharmaceuticals | SEC FORM 4 Sold | $177K332 at $534.16 | filing |
| 9 Jan 2026filed 13 Jan 2026 | MDGL Madrigal PharmaceuticalsPharmaceuticals | SEC FORM 4 Sold | $79K148 at $535.29 | filing |
| 9 Jan 2026filed 13 Jan 2026 | MDGL Madrigal PharmaceuticalsPharmaceuticals | SEC FORM 4 Sold | $254K473 at $536.02 | filing |
| 9 Jan 2026filed 13 Jan 2026 | MDGL Madrigal PharmaceuticalsPharmaceuticals | SEC FORM 4 Sold | $261K487 at $536.88 | filing |
News
Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)MDGL · manilatimes.net · 15 Oct 2026Madrigal Pharmaceuticals (NASDAQ:MDGL) & Coya Therapeutics (NASDAQ:COYA) Critical ContrastMDGL · themarketsdaily.com · 9 Oct 2026Financial Analysis: Madrigal Pharmaceuticals (NASDAQ:MDGL) and MacroGenics (NASDAQ:MGNX)MDGL · dailypolitical.com · 6 Oct 2026
0 headlines in the last 90 days name Paul A. Friedman; 3 articles from the last 14 days about the 1 company they traded most, at most three about any one of them.